ESMO 2019 | Optimism for apatinib in gastric cancer
Steven Norton, MBA, PhD, Elevar Therapeutics, Salt Lake City, UT, discusses initial results from the ANGEL study (NCT03042611): the first global trial of apatinib in advanced or metastatic gastric cancer. Dr Norton lists the toxicities seen during the trial but states overall results are promising. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Get great new content delivered to your inboxSign up